(TACT) Repurchases 490,000 Shares of Company’s Common Stock

TransAct Technologies Incorporated (Nasdaq: TACT), a global leader in market-specific solutions, including printers, terminals, software and other products for transaction-based and other industries, today repurchased 490,000 shares of its common stock at $8.75 per share, for total consideration of approximately $4.3 million. The shares were repurchased at market and represent approximately 5.6% of the Company’s outstanding common stock.

About TransAct Technologies Incorporated

TransAct Technologies Incorporated is a leader in developing and manufacturing market-specific solutions, including printers, terminals, software and other products for transaction-based and other industries. These industries include casino and gaming, lottery, food safety, banking, point-of-sale, hospitality, oil and gas, and medical and mobile. Each individual market has distinct, critical requirements for printing and the transaction is not complete until the receipt and/or ticket is produced. TransAct printers and products are designed from the ground up based on market-specific requirements and are sold under the Ithaca®, Epic, EPICENTRAL® and Printrex® product brands. TransAct distributes its printers through OEMs, value-added resellers, selected distributors, and direct to end-users. TransAct has over 2.4 million printers installed around the world. TransAct is also committed to providing world-class printer service, spare parts, accessories and printing supplies to its growing worldwide installed base of printers. Through its TransAct Services Group, TransAct provides a complete range of supplies and consumable items used in the printing and scanning activities of customers in the hospitality, banking, retail, gaming, government and oil and gas exploration markets. Through its webstore, http://www.transactsupplies.com, and a direct selling team, TransAct addresses the on-line demand for these products. TransAct is headquartered in Hamden, CT. For more information, please visit http://www.transact-tech.com or call 203.859.6800.

(CEDU) to Announce Q2 Financials on September 11

BEIJING, Aug. 23, 2013 — ChinaEdu Corporation (NASDAQ: CEDU) (“ChinaEdu” or “the Company”), a leading educational services provider in China, today announced that the Company will release its unaudited financial results for the second quarter ended June 30, 2013 after the U.S. markets close on September 11, 2013. ChinaEdu’s management will hold an earnings conference call at 8:00 a.m. U.S. Eastern Time on September 12, 2013 (8:00 p.m. Beijing/Hong Kong Time on September 12, 2013).

Dial-in details for the earnings conference call are as follows:

A live and archived webcast of the conference call will be available on the investor relations page of ChinaEdu’s website at http://ir.chinaedu.net and a replay of the conference call may be accessed by phone until September 18, 2013.

Dial-in numbers for the replay are as follows:

About ChinaEdu

ChinaEdu Corporation is an educational services provider in China, incorporated as an exempted limited liability company in the Cayman Islands. Established in 1999, the Company’s primary business is to provide comprehensive services to the online degree programs of leading Chinese universities. These services include academic program development, technology services, enrollment marketing, student support services and finance operations. The Company’s other lines of businesses include the operation of private primary and secondary schools, online interactive tutoring services and providing marketing, support for international and elite curriculum programs and online learning community for adult students.

The Company believes it is the largest service provider to online degree programs in China in terms of the number of higher education institutions that are served and the number of student enrollments supported. The Company currently provides technical, recruiting and other services to 27 universities with online degree programs and provides services and support to 11 additional universities that are awaiting regulatory approval to launch their online programs. Of these 38 universities, 13 of them have entered into collaborative alliances with ChinaEdu, ranging from 15 to 50 years in length. Eight of them have entered into technology service agreements, ranging from 3 to 20 years in length. ChinaEdu also performs recruiting services through its nationwide learning center network for 23 universities, including 6 with which the Company has either established collaborative alliances or entered into technology service agreements.

For investor and media inquiries, please contact:

Helen Plummer
Senior Investor Relations Coordinator
ChinaEdu Corporation
Phone: +1 (908) 442-9395
E-mail: helen@chinaedu.net

Simon Mei
Chief Financial Officer
ChinaEdu Corporation
Phone: +86 8418-7301
E-mail: simon@chinaedu.net

(MSFT) CEO Steve Ballmer to retire within 12 months

Board of directors initiates succession process; Ballmer remains CEO until successor is named.

REDMOND, Wash., Aug. 23, 2013 — Microsoft Corp. today announced that Chief Executive Officer Steve Ballmer has decided to retire as CEO within the next 12 months, upon the completion of a process to choose his successor. In the meantime, Ballmer will continue as CEO and will lead Microsoft through the next steps of its transformation to a devices and services company that empowers people for the activities they value most.

“There is never a perfect time for this type of transition, but now is the right time,” Ballmer said. “We have embarked on a new strategy with a new organization and we have an amazing Senior Leadership Team. My original thoughts on timing would have had my retirement happen in the middle of our company’s transformation to a devices and services company. We need a CEO who will be here longer term for this new direction.”

The Board of Directors has appointed a special committee to direct the process. This committee is chaired by John Thompson, the board’s lead independent director, and includes Chairman of the Board Bill Gates, Chairman of the Audit Committee Chuck Noski and Chairman of the Compensation Committee Steve Luczo. The special committee is working with Heidrick & Struggles International Inc., a leading executive recruiting firm, and will consider both external and internal candidates.

“The board is committed to the effective transformation of Microsoft to a successful devices and services company,” Thompson said. “As this work continues, we are focused on selecting a new CEO to work with the company’s senior leadership team to chart the company’s course and execute on it in a highly competitive industry.”

“As a member of the succession planning committee, I’ll work closely with the other members of the board to identify a great new CEO,” said Gates. “We’re fortunate to have Steve in his role until the new CEO assumes these duties.”

Founded in 1975, Microsoft (Nasdaq: MSFT) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

(IBCP) Announces Pricing Of Public Offering Of Common Stock

IONIA, Mich., Aug. 23, 2013 — Independent Bank Corporation (NASDAQ: IBCP) (“Independent” or the “Company”) announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a price of $7.75 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock sold pursuant to this transaction to cover over-allotments, if any.

The Company intends to use the net proceeds from this offering to redeem all of the shares of its Fixed Rate Cumulative Mandatorily Convertible Preferred Stock, Series B (including all accrued and unpaid dividends) and related Warrant, both issued to the U.S. Department of the Treasury under the Troubled Asset Relief Program Capital Purchase Program, for an aggregate payment of $81 million pursuant to the terms and conditions of the previously announced Securities Purchase Agreement, dated July 26, 2013, between the Company and the U.S. Department of the Treasury.  The Company intends to use any remaining net proceeds for general corporate purposes.

The offering of common stock may be made only by means of a prospectus.  Keefe, Bruyette & Woods, a Stifel company, is the sole book-running manager in the offering.  Sandler O’Neill + Partners, L.P. and Boenning & Scattergood, Inc. are acting as co-managers for the offering.

A registration statement relating to the shares is effective with the Securities and Exchange Commission (“SEC”), and a prospectus relating to the offering has been filed with the SEC.  Copies of the prospectus may be obtained from the SEC’s Web site at: www.sec.gov.  Alternatively, you may obtain copies of the prospectus by contacting Keefe, Bruyette & Woods, Inc., Attention: Equity Capital Markets, 787 Seventh Avenue, 4th Floor, New York, NY 10019, telephone (800) 966-1559.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Independent Bank Corporation

Independent Bank Corporation (NASDAQ: IBCP) is a Michigan-based bank holding company with total assets of approximately $2.1 billion.  Founded as First National Bank of Ionia in 1864, Independent Bank Corporation currently operates a 71-branch network across Michigan’s Lower Peninsula through one state-chartered bank subsidiary.  This subsidiary (Independent Bank) provides a full range of financial services, including commercial banking, mortgage lending, investments and title services.  Independent Bank Corporation is committed to providing exceptional personal service and value to its customers, stockholders and the communities it serves.

For more information, please visit our Web site at:  www.IndependentBank.com.

Any statements in this news release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “estimate,” “project,” “may” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are predicated on management’s beliefs and assumptions based on information known to Independent Bank Corporation’s management as of the date of this news release and do not purport to speak as of any other date. Forward-looking statements include descriptions of plans and objectives of Independent Bank Corporation’s management for the expected use of the proceeds received from the offering described herein, future or past operations, products or services, and forecasts of the Company’s revenue, earnings or other measures of economic performance. Such statements reflect the view of Independent Bank Corporation’s management as of this date with respect to future events and are not guarantees of future performance, involve assumptions and are subject to substantial risks and uncertainties, such as the changes in Independent Bank Corporation’s plans, objectives, expectations and intentions. Should one or more of these risks materialize or should underlying beliefs or assumptions prove incorrect, the Company’s actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include the ability of Independent Bank Corporation to meet the objectives of its capital plan, the ability of Independent Bank to remain well-capitalized under federal regulatory standards, the pace of economic recovery within Michigan and beyond, changes in interest rates, changes in the accounting treatment of any particular item, the results of regulatory examinations, changes in industries where the Company has a concentration of loans, changes in the level of fee income, changes in general economic conditions and related credit and market conditions, and the impact of regulatory responses to any of the foregoing. Forward-looking statements speak only as of the date they are made. Independent Bank Corporation does not undertake to update forward-looking statements to reflect facts, circumstances, assumptions or events that occur after the date the forward-looking statements are made. For any forward-looking statements made in this news release or in any documents, Independent Bank Corporation claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

(EAC) New VP of Safety, Security and Compliance Appointed

Erickson Air-Crane Incorporated (NASDAQ: EAC) (“Erickson” or “the Company”), a leading global provider of aviation services to a diverse mix of commercial and government customers, and the vertically-integrated manufacturer and operator of the powerful heavy-lift Erickson S-64 Aircrane helicopter, announced today that it has appointed Dr. Michael D. New as the Company’s Vice President of Safety, Security, and Compliance. Dr. New will have responsibility for those areas across the Company’s global base of operations and, with a 30-year career in aviation as both a highly qualified pilot and safety executive, brings a wealth of experience and expertise to this position.

Udo Rieder, Chief Executive Officer of Erickson, commented, “We are continuing to build a world-class team of executives to lead our company forward and take full advantage of the opportunities for growth and diversification that lie ahead. We welcome Michael as a key member of our team, and look forward to the benefit of his expertise and leadership.”

Dr. New joins the Company from his most recent position as Senior Vice President, Corporate Safety, Security, and Compliance with Korean Air. Dr. New previously held senior management and engineering positions at several companies, including Aveos Fleet Performance, Inc., United Continental Holdings, Inc., Bristow Group, Delta Air Lines, and Lockheed Martin. He began his career as a US Air Force pilot and then as an airline captain and instructor, having received type-ratings on the B-737, B-757, and B-767. Dr. New has received advanced degrees including a Ph.D. with a focus on human factors engineering from the Georgia Institute of Technology.

About Erickson Air-Crane Incorporated

Erickson Air-Crane Incorporated is a leading global provider of aviation services to a diverse mix of commercial and government customers. The Company currently operates a diverse fleet of 85 rotary-wing and fixed wing aircraft, including a fleet of 20 heavy-lift S-64 Aircranes. This fleet supports a wide and worldwide variety of government and commercial customers, across a broad range of aerial services, including critical supply and logistics for deployed military forces, humanitarian relief, firefighting, timber harvesting, infrastructure construction, and crewing. The Company also maintains a vertical manufacturing capability for the S-64 Aircrane, related components, and other aftermarket support and maintenance, repair, and overhaul services for the Aircrane and other aircraft.

Founded in 1971, Erickson Air-Crane is headquartered in Portland, Oregon and maintains facilities and operations in North America, South America, the Middle East, Africa and Asia-Pacific. For more information, please visit www.ericksonaircrane.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. You can identify forward-looking statements by words such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other comparable terminology. These forward-looking statements are based on management’s current expectations but they involve a number of risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of risks and uncertainties, which include: the possibility that we do not complete the acquisition of the Brazilian air logistics business, or realize the benefits of the acquisition of EHI or the Brazilian air logistics business on a timely basis or at all; our ability to integrate these businesses successfully or in a timely and cost-efficient manner; our ability to successfully enter new markets and manage international expansion; that we do not have extensive operating history in the aerial services segments in which EHI and Air Amazonia operate nor with the types of aircraft we acquired in the EHI acquisition and those we would in the Air Amazonia acquisition; that we do not have extensive operating history in South America, the Middle East and Africa, which are where EHI and Air Amazonia provide aerial services; that we do not have any operating history providing services to the Department of Defense and related customers and projects, which are segments to which EHI provides services; that the anticipated reduction in troops in Afghanistan in the near-term may adversely affect EHI; that EHI operates in certain dangerous and war-affected areas, which may result in hazards to its fleet and personnel; that, despite our current indebtedness levels, we and our subsidiaries may still incur significant additional indebtedness; our failure to obtain any required financing on favorable terms; our safety record; the hazards associated with our helicopter operations, which involve significant risks and which may result in hazards that may not be covered by our insurance or may increase the cost of our insurance; compliance with debt obligations and our substantial indebtedness, which could adversely affect our financial condition and impair our ability to grow and operate our business; cancellations; reductions or delays in customer orders; our ability to collect on customer receivables; weather and seasonal fluctuations that impact our Aircrane and other aerial services activities; competition; reliance on a small number of large customers; the impact of short-term contracts; the availability and size of the Aircrane fleet; the ability to implement production rate changes; the impact of government spending; the impact of product liability and product warranties; the ability to attract and retain qualified personnel; the impact of environmental and other regulations, including FAA regulations and similar international regulations; our ability to accurately forecast financial guidance; our ability convert backlog into revenues and appropriately plan expenses; worldwide economic conditions (including conditions in Greece and Italy); our reliance on a small number of manufacturers; the necessity to provide components or services to owners and operators of aircraft; our ability to effectively manage our growth; our ability to keep pace with changes in technology; our ability to adequately protect our intellectual property; our ability to successfully enter new markets and manage international expansion; our ability to expand and diversify our customer base; our ability to expand and market manufacturing and maintenance, repair and overhaul services; the potential unionization of our employees; the fluctuation in the price of fuel; our ability to access public or private debt markets; the impact of equipment failures or other events impacting the operation of our factories; and our ability to successfully manage any future acquisitions; as well as other risks and uncertainties more fully described under the heading “Risk Factors” in our most recently filed Annual Report on Form 10-K as well as the other reports we file with the SEC.

You should not place undue reliance on any forward-looking statements. Erickson Air-Crane assumes no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable laws.

(AMOT) to Acquire Globe Motors, Inc.

Allied Motion Technologies Inc. (NASDAQ: AMOT) announced today that it has entered into a definitive agreement to acquire all of the outstanding shares of Globe Motors, Inc. from Safran USA, Inc., on a cash free, debt free basis, for approximately $90 million in cash. The transaction is expected to close within 60 days and is subject to certain customary conditions including regulatory approvals and completion of the financing documentation.

Founded in 1940, Globe Motors employs more than 500 employees worldwide and is headquartered in Dayton, Ohio with additional operations in Dothan, Alabama, Reynosa, Mexico and Oporto, Portugal. Globe has a well-established and strong industry reputation as a high quality provider of customized and innovative motion solutions to meet the needs of its customers in selected target market segments. For the year ended December 31, 2012, Globe recorded revenues of approximately $106 million.

“Globe Motors has a solid financial track record that will be accretive to our earnings and will also more than double the size of Allied Motion in terms of revenues,” commented Dick Warzala, President and Chief Executive Officer of Allied Motion. “Strategically, Globe fits very well with our company, as it creates critical mass and expands our global reach while providing the opportunity for us to leverage the combined technology/know-how, sales and marketing channels, material sourcing and production capabilities/footprint of both companies. While there is some overlap in technology and in the customer base, the companies are very complementary to each other and will provide additional market diversification and cross-selling opportunities for the combined entity in the future. We are enthusiastic about the prospects of our company and confident that the utilization of Allied Systematic Tools will lead us to continuous improvements in Quality, Delivery, Cost and Innovation and will create significant value in the future for all stakeholders of both Globe and Allied. Last but not least, we at Allied Motion are excited to have the very professional and experienced management team and employees of Globe join the Allied Team as we continue our journey in providing Motion Solutions That Change the Game and create significant value for our customers in our served market segments.”

About Allied Motion Technologies Inc.

Headquartered in Amherst, New York, Allied Motion designs, manufactures and sells motion control products into applications that serve many industry sectors. Allied Motion is a leading supplier of precision and specialty motion control components and systems to a broad spectrum of customers throughout the world.

Cautionary Note Regarding Forward-Looking Statements

Allied Motion makes forward-looking statements in this press release which represent its expectations or beliefs about future events and financial performance. Forward-looking statements are identifiable by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward looking statements made in this press release, include, but are not limited to, statements concerning: the expected timetable for consummation of the transaction; Globe Motors’ business complementing and expanding Allied Motion’s existing operations and international presence; growth prospects; accretion to earnings and other potential benefits and synergies of the transaction.

You are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future events and involve risks, uncertainties and other known and unknown factors that may cause actual results and performance to be materially different from any future results or performance expressed or implied by such forward-looking statements, including, but not limited to, the failure to consummate, or a delay in the consummation of, the transaction; general economic conditions and conditions affecting the industries in which Allied Motion and Globe Motors operate; the uncertainty of obtaining regulatory approvals; Allied Motion’s ability to successfully integrate Globe Motors’ operations and employees with Allied Motion’s existing business; the ability to realize anticipated growth, synergies and cost savings; and Globe Motors’ performance and maintenance of important business relationships.

Allied Motion makes no commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement.

(AGX) Moxie Liberty LLC Financing and Sale is Consummated

Argan, Inc. (NYSE MKT: AGX) announced that Panda Power Funds has completed the acquisition and successful financing of Moxie Liberty LLC. Gemma Power Inc. (GPI), a wholly-owned subsidiary of Argan Inc., has been funding Moxie Liberty in the development of an 829 MW natural gas-fired power plant in Bradford County, Pennsylvania. As a result of the sale, GPI is receiving development success fees and repayment of the working capital advances plus accrued interest from the proceeds. Gemma Power Systems LLC (GPS), another subsidiary of Argan, has been awarded the EPC Agreement to design and build the power plant. The EPC Agreement has been assigned to Gemma-Lane Liberty Partners (GLLP), a joint venture between Gemma Power Systems and The Lane Construction Corporation for the construction of the plant. GPS holds a 75% interest in GLLP.

Commenting on the Moxie Liberty project, Rainer Bosselmann, Chairman and Chief Executive Officer stated, “We are pleased to join forces with Panda Power Funds in constructing this large scale power facility.”

About Argan, Inc.

Argan’s primary business is designing and building energy plants through its Gemma Power Systems subsidiaries. These energy plants include traditional natural gas-fired power plants as well as alternative energy facilities including biodiesel, ethanol and renewable energy sources such as wind power. Argan also owns Southern Maryland Cable, Inc.

Certain matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties including, but not limited to: (1) the Company’s ability to achieve its business strategy while effectively managing costs and expenses; (2) the Company’s ability to successfully and profitably integrate acquisitions; and (3) the continued strong performance of the energy sector. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in Argan’s filings with the Securities and Exchange Commission. In addition, reference is hereby made to cautionary statements with respect to risk factors set forth in the Company’s most recent reports on Form 10-K and 10-Q, and other SEC filings.

(HPOL) Reports Q4, FY13 Results

Exceeds Full Year Adjusted EBITDA Guidance; Meets Full Year Revenue Guidance

ROCHESTER, N.Y., Aug. 22, 2013 — Harris Interactive Inc. (NASDAQ: HPOL), a leading global market research firm, today announced its fourth quarter and full year fiscal 2013 financial results.

Al Angrisani, President and Chief Executive Officer of Harris Interactive, commented, “We are pleased with our full fiscal 2013 financial performance, which led to profitability that was above the high end of our adjusted EBITDA guidance and represented more than a 20% year over year improvement. We also are pleased that we generated sufficient cash in fiscal 2013 to pay off all our outstanding debt prior to maturity, and increased our net cash position by more than $10 million. Going forward, we will begin the transition away from the turnaround of the last two fiscal years to a business model focused on investing in the business for long term shareholder value creation.”

Eric Narowski, Chief Financial Officer of Harris Interactive, commented, “Based on current market conditions and forecasts for the fiscal year ending June 30, 2014, the Company projects adjusted EBITDA of between $14.5 and $16.5 million.”

Fourth Quarter and Full Year Fiscal 2013 Results Conference Call and Webcast Access

Al Angrisani, President and Chief Executive Officer, will host a conference call to discuss these results on Thursday, August 22, 2013, at 5:00 p.m. ET. Formal remarks will be followed by a question and answer session.

To access the conference call, please dial toll-free  877.303.9858 in the United States and Canada, or 408.337.0139 internationally.

A live webcast of the conference call also will be accessible via the Investor Relations section of our website at http://ir.harrisinteractive.com/, where an archived replay of the webcast will be available for 30 days following the call. No telephone replay of the conference call will be provided. This media release will be available under the Investor Relations section of our website at http://ir.harrisinteractive.com/ prior to the call.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press release and oral statements made by the Company on its conference call constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, among others, statements as to future economic performance, projections as to financial items, estimates, and plans and objectives for future operations, products and services. In some cases, you can identify forward-looking statements by terminology such as, “may”, “should”, “expects”, “plans”, “anticipates”, “feel”, “believes”, “estimates”, “predicts”, “potential”, “continue”, “consider”, “possibility”, or the negative of these terms or other comparable terminology. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, without limitation, risks detailed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, as updated quarterly in our Quarterly Reports on Form 10-Q to reflect additional material risks. The Company has filed its reports on Forms 10-K and 10-Q with the Securities and Exchange Commission, and they are available under the Investor Relations section of our website at http://ir.harrisinteractive.com/. Risks and uncertainties also include the continued volatility of the global macroeconomic environment and its impact on the Company and its clients, the Company’s ability to sustain and grow its revenue base, the Company’s ability to maintain and improve cost efficient operations, the impact of reorganization, restructuring and related charges, quarterly variations in financial results, the Company’s ability to maintain compliance with certain NASDAQ listing requirements, actions of competitors and the Company’s ability to develop and maintain products and services attractive to the market.

You are urged to consider these factors carefully in evaluating such forward-looking statements and are cautioned not to place undue reliance on them. The forward-looking statements are qualified in their entirety by this cautionary statement.

About Harris Interactive

Harris Interactive is one of the world’s leading market research firms, leveraging research, technology, and business acumen to transform relevant insight into actionable foresight. Known widely for the Harris Poll® and for pioneering innovative research methodologies, Harris offers proprietary solutions in the areas of market and customer insight, corporate brand and reputation strategy, and marketing, advertising, public relations and communications research. Harris possesses expertise in a wide range of industries including health care, technology, public affairs, energy, telecommunications, financial services, insurance, media, retail, restaurant, and consumer package goods. Additionally, Harris has a portfolio of multi-client offerings that complement our custom solutions while maximizing our client’s research investment. Serving clients in more than 196 countries and territories through our North American and European offices, Harris specializes in delivering research solutions that help us – and our clients-stay ahead of what’s next. For more information, please visit www.harrisinteractive.com.

HPOL – E

Press Contact:
Michael T. Burns
Investor Relations
Harris Interactive Inc.
800-866-7655 x7328
mburns@harrisinteractive.com

(HZNP) Announces Settlement of DUEXIS® Patent Litigation

(SARA) Test Results on Horizontal Well in Breton Sound 32

Saratoga Resources, Inc. (NYSE MKT: SARA; the “Company” or “Saratoga”) today provided an update on its recent development drilling activity in Breton Sound Block 32 field.

The SL 1227-25 “Rocky” well, in 13 feet of water depth, was spud with the Parker 77B inland barge rig on July 4^th. A directional pilot well was drilled to a total depth (“TD”) of 6254’ measured depth (“MD”)/5858’ true vertical depth (“TVD”), as planned, before plugging back and drilling a 750’ sidetrack horizontal section to a TD of 7178’ MD/5790’ TVD, reached on 24^th July. The well was subsequently completed and the rig moved to our Zeke location in the same field on August 3^rd. The Rocky well tested on August 20, 2013 at a gross rate of approximately 600 BOPD and 120 MCFPD on a 16/64” choke with FTP of 650 psi, or net 508 BOEPD, and has been tied back to Saratoga’s Breton Sound 32 platform. The rate continues to improve as the well stabilizes. Final costs on the Rocky well are expected to come in below the pre-drill AFE.

The SL 1227-26 “Zeke” well was spud on August 5^th and drilled as a directional hole to a TD of 6,430’ MD/5836.7’ TVD. The well is a high angle directional well, with a short reach horizontal section, in the same 5800’ sand as Rocky but in the eastern portion of Breton Sound 32 field. There is also an uphole 5,750’ sand recompletion opportunity in the Zeke well, which can be accessed in the future. The Zeke well is awaiting completion and testing. If successful, the Zeke well will also be tied back to Saratoga’s Breton Sound 32 platform.

Andrew C. Clifford, President, stated, “Our successful completion of Rocky is a significant milestone for Saratoga and is the first of what we believe are a number of high impact horizontal opportunities already identified in Breton Sound 32 and other fields. Previous horizontal completions within our leasehold footprint, including four in Breton Sound 32 field, one in Main Pass 25 field and one in Grand Bay field, have recovered 2.5 to 3 times more hydrocarbons than a vertical completion in the same reservoir and initial production rates were up to 3 times higher with higher rates sustained for a longer period before decline set in. Zeke targeted the same sand as Rocky and is presently awaiting completion and testing. Subject to completion and testing of Zeke, we expect to have both wells producing before the end of August.

Pending completion of Zeke, we are evaluating other drilling candidates such as the Charlie well, also in Breton Sound 32 field, and several opportunities in Grand Bay. This is consistent with our strategy to grow production organically via the drill-bit with our primary objective being higher impact wells like Rocky.”

About Saratoga Resources

Saratoga Resources is an independent exploration and production company with offices in Houston, Texas and Covington, Louisiana. Principal holdings cover 52,033 gross/net acres, mostly held by production, located in the transitional coastline and protected in-bay environment on parish and state leases of south Louisiana and in the shallow Gulf of Mexico Shelf. Most of the company’s large drilling inventory has multiple pay objectives that range from as shallow as 1,000 feet to the ultra-deep prospects below 20,000 feet in water depths ranging from less than 10 feet to a maximum of approximately 80 feet. For more information, go to Saratoga’s website at www.saratogaresources.com and sign up for regular updates by clicking on the Updates button.

Forward-Looking Statements

This press release includes certain estimates and other forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding future production rates and drilling results, costs of drilling, timing of completion of wells and commencement of production, ultimate recoveries from wells, ability to fund drilling operations, and the ultimate outcome of such efforts. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “assumes”, “seeks”, “estimates”, “should”, and variations of these words and similar expressions, are intended to identify these forward-looking statements. While we believe these statements are accurate, forward-looking statements are inherently uncertain and we cannot assure you that these expectations will occur and our actual results may be significantly different. These statements by the Company and its management are based on estimates, projections, beliefs and assumptions of management and are not guarantees of future performance. Important factors that could cause actual results to differ from those in the forward-looking statements include the factors described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update or revise any forward-looking statement based on the occurrence of future events, the receipt of new information, or otherwise.

(XRSC) and Samsung Mobile Join Forces Over Trucking Industr

Innovative, Comprehensive Solution From XRS and Samsung Mobile Will Be the First of Its Kind in Trucking, Providing Industry’s First Free Compliance Solution Pre-Loaded With XRS

Innovative, Comprehensive Solution From XRS and Samsung Mobile Will Be the First of Its Kind in Trucking, Providing Industry’s First Free Compliance Solution Pre-Loaded With XRS

(DMND) Announces Proposed Agreement to Settle Private Securities Class Action

Company Provides Unaudited Preliminary Fourth Quarter and Full Year Fiscal 2013 Expectations for Net Sales, Gross Margin and Adjusted EBITDA

SAN FRANCISCO, Aug. 21, 2013 (GLOBE NEWSWIRE) — Diamond Foods, Inc. (Nasdaq:DMND) (“Diamond”) today announced that it has reached a proposed agreement, subject to Court approval, to settle the private securities class action pending against the Company and two of its former officers.

Under the terms of the proposed settlement, Diamond would pay a total of $11 million in cash and issue 4.45 million shares of common stock to a Settlement Fund to resolve all claims asserted on behalf of investors who purchased or otherwise acquired Diamond stock between October 5, 2010 and February 8, 2012. The proposed settlement further provides that Diamond denies all claims of wrongdoing or liability.

A substantial portion of the $11 million in cash would be funded by Diamond’s insurers. With respect to the 4.45 million shares of common stock, Diamond would have the ability to privately place, or conduct a public offering of, the shares with the consent of the lead plaintiff and its counsel, prior to distribution of the Settlement Fund. In that event, the Settlement Fund would include the proceeds of the offering in lieu of the settlement shares.

If this proposed settlement is approved by the Court, a notice to the Class members will be sent with information regarding the allocation and distribution of the Settlement Fund and instructions on procedures to follow to make a claim on the Settlement Fund.

“We believe this proposed settlement eliminates the burden of further time, expense and risk related to the class action, allowing the Diamond team to move forward fully focused on expanding the reach of our leading brands and executing on our strategic and operational initiatives for growth,” stated Brian J. Driscoll, Diamond’s Chief Executive Officer. “We continue to strengthen our business and are pleased that our fourth quarter performance enables us to complete fiscal year 2013 in an improved financial position.”

The Company also announced unaudited preliminary fourth quarter and full year fiscal 2013 expectations for net sales, gross margin and adjusted EBITDA as follows:

Note: Adjusted EBITDA, a non-GAAP financial measure, for the fourth quarter of fiscal 2013 excludes the warrant liability loss, consulting fees, legal expenses, and other costs. Adjusted EBITDA for full year fiscal 2013 also excludes restatement related accounting and legal expenses, Fishers plant closure and other costs.

The Company does not plan to provide preliminary financial information in the future other than in unique circumstances, or in the event of a material event that requires disclosure. The Company plans to release fourth quarter and full year fiscal 2013 earnings in late September.

About Diamond Foods

Diamond Foods is an innovative packaged food company focused on building and energizing brands including Kettle® Chips, Emerald® snack nuts, Pop Secret® popcorn, and Diamond of California® nuts. Diamond’s products are distributed in a wide range of stores where snacks and culinary nuts are sold. For more information visit our corporate web site: www.diamondfoods.com.

Note Regarding Forward-looking Statements

This press release includes forward-looking statements, including projections as to net sales, gross margin, Adjusted EBITDA, benefits of settling litigation, progress on strategic initiatives, Court approval of the settlement of the securities class action litigation and the possibility of offering the settlement securities to a private purchaser or the public.  We have based these forward-looking statements on our assumptions, expectations and projections about future events only as of the date of this press release, and we make such forward-looking statements pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Many of our forward-looking statements include discussions of trends and anticipated developments under the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the periodic reports that we file with the SEC. We use the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “seek,” “may” and other similar expressions to identify forward-looking statements. You also should carefully consider other cautionary statements elsewhere in the reports and in other documents we file from time to time with the SEC. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this report. Actual results may differ materially from what we currently expect because of many risks and uncertainties, including: the failure to obtain preliminary or final Court approval of the proposed settlement or delay in obtaining such approval; risks related to decisions by stockholders to opt out of or object to the proposed settlement; the dilutive impact of the issuance of the proposed settlement shares on our stock price; the potential impact on our stock price of sales of the proposed settlement shares into the public market; risks relating to our leverage and its effect on our ability to respond to changes in our business, markets and industry; increase in the cost of our debt; failure to comply with debt covenants; inability to raise additional capital and the possible dilutive impact of raising such capital; risks relating to litigation and regulatory proceedings; uncertainties relating to relations with growers; availability and cost of walnuts and other raw materials; increasing competition and possible loss of key customers; and general economic and capital markets conditions.

CONTACT: Investors:
         ICR
         Katie Turner
         415-230-7952

         Media:
         ICR
         Anton Nicholas
         Jessica Liddell
         415-445-7431

(INCY) Top-Line Results, Phase II Trial of Ruxolitinib in Pancreatic Cancer

Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 and JAK2 inhibitor, in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer. The hazard ratio (HR) for overall survival (OS) in the intent to treat population was 0.79 (one-sided p=0.12), and in a pre-specified subgroup analysis conducted in patients identified prospectively as most likely to benefit from JAK pathway inhibition, the HR for OS was 0.47 (one-sided p=0.005). Within this subgroup of patients, which represented 50% of the randomized population, 6 month survival in the ruxolitinib arm was 42% vs. 11% for placebo. Durable tumor responses were only observed in patients receiving ruxolitinib, and ruxolitinib treated patients achieved a significant improvement in body weight relative to placebo.

“Results of the RECAP trial provide the first evidence that JAK inhibition is active in this disease and suggest a demonstrable survival benefit in a well-defined group of patients with refractory metastatic pancreatic cancer who can be identified without the development of a companion diagnostic test. Coupled with the overall survival benefit observed in the ongoing Phase III trials in myelofibrosis, these results solidify our belief in the therapeutic opportunity that exists for Jakafi, and provide us with an acceleration strategy to advance our JAK1 inhibitor portfolio into additional areas of unmet medical need,” stated Paul A. Friedman, M.D., Incyte’s President and Chief Executive Officer.

Richard S. Levy, Incyte’s Executive Vice President and Chief Drug Development and Medical Officer added, “Advanced pancreatic cancer is a devastating disease, and the RECAP study has provided us with a unique opportunity to bring ruxolitinib forward into Phase III development in a population with no attractive treatment options. We look forward to working with the FDA to define the core components of the Phase III program in pancreatic cancer as rapidly as possible, and in parallel, leveraging these results to expand our ruxolitinib and JAK1 inhibitor programs into additional solid tumor populations, including those that may benefit from selective JAK1 inhibition.”

Full results of the RECAP trial are expected to be presented at a future scientific meeting.

Safety

Ruxolitinib in combination with capecitabine was generally well tolerated in this study. Among patients receiving ruxolitinib plus capecitabine 12% discontinued therapy for an adverse event, compared with 20% who received capecitabine alone. The rates of new onset grade 3 anemia, thrombocytopenia or neutropenia were 16%, 2% and 0%, respectively, among patients receiving ruxolitinib plus capecitabine and were 2%, 3% and 2%, respectively, among patients receiving capecitabine alone.

About The RECAP Trial

The purpose of this initial proof-of-concept study was to determine whether ruxolitinib in combination with capecitabine could improve the overall survival of patients with refractory metastatic pancreatic cancer as compared to capecitabine alone. RECAP included pre-specified analyses to determine the base line characteristics of patients most likely to benefit from treatment with ruxolitinib. The study included a total of 136 patients and consisted of an open-label, safety run-in period involving nine patients to determine the safety of the ruxolitinib and capecitabine combination. This was followed by a double-blind study of 127 patients randomized 1 to 1 to capecitabine plus ruxolitinib or capecitabine plus placebo. Patients received treatment as long as the regimen was tolerated or the patient did not meet any of the discontinuation criteria. In the event of disease progression, capecitabine therapy was discontinued while treatment with ruxolitinib or placebo continued unless patients withdrew consent for further participation in the trial. In addition to the primary endpoint of overall survival, secondary endpoints included progression free survival, body weight and nutritional markers, tumor response rate, quality of life outcomes and pain status.

About Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of cancer-related death in the US and the eighth leading cause of cancer-related death worldwide. For patients with advanced pancreatic cancer, the 5-year overall survival rate is less than 1 percent. Most patients die within the first year. Pancreatic cancer has the lowest 5-year overall survival rate of any cancer in the US. In Europe, the reported survival rate is less than 10 percent survival at five years. Unfortunately, most patients do not exhibit symptoms until their disease is advanced. Additionally, pancreatic cancer progresses and metastasizes rapidly, highlighting the need to identify high-risk candidates early.

About Ruxolitinib

Ruxolitinib is an oral, selective inhibitor of Janus kinases 1 and 2 (JAK1 and JAK2). Ruxolitinib, brand name Jakafi^®, is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. This life-threatening blood cancer is characterized by bone marrow failure, enlarged spleen (splenomegaly) and debilitating symptoms.

Important Safety Information

Jakafi can cause serious side effects including:

Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

The most common side effects of Jakafi include dizziness and headache.

These are not all the possible side effects of Jakafi. Ask your healthcare provider or pharmacist for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had liver or kidney problems, are on dialysis, or have any other medical condition. Do not drink grapefruit juice while taking Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information available at www.jakafi.com, which includes a more complete discussion of the risks associated with Jakafi.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including without limitation, statements as to results of the RECAP trial being expected to define and support a pivotal registration program for ruxolitinib in metastatic pancreatic cancer, that results of the RECAP trial suggest a demonstrable survival benefit in a well-defined group of patients with refractory metastatic pancreatic cancer who can be identified without the development of a companion diagnostic test, our plans to work with the FDA to define the core components of the Phase III program in pancreatic cancer as rapidly as possible and to expand and advance our JAK1 program into additional solid tumor populations that may benefit from selective JAK1 inhibition and areas of unmet medical need, and our expectation that full results of the RECAP trial will be presented at a future scientific meeting, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of ruxolitinib, risks related to market competition, the results of further research and development, risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, the ability to enroll sufficient numbers of subjects in clinical trials, other market or economic factors and technological advances, unanticipated delays, the ability of Incyte to compete against parties with greater financial or other resources, and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2013.

Incyte disclaims any intent or obligation to update these forward-looking statements.

(GALE) Expands NeuVax™ Intellectual Property With European Allowance

PORTLAND, Ore., Aug. 21, 2013 — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the European Patent Office notified the Company of an intention to grant a Pharmaceutical Use Patent for NeuVax™ (nelipepimut-S). The patent covers the use of NeuVax as a vaccine for the prevention of relapse in breast cancer patients with an immunochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression and a fluorescence in situ hybridization (FISH) rating of less than 2.0 for HER2/neu gene expression. The patent protection is afforded in all of the European countries and will expire in April 2028.

“This patent expands our intellectual property protection for NeuVax in Europe, and further validates our novel, cancer immunotherapy approach to preventing the recurrence of breast cancer in women who otherwise have no treatment options,” said Mark J. Ahn, Ph.D., President and CEO. “NeuVax is the only drug currently in Phase 3 development for patients with early-stage, node-positive breast cancer with low-to-intermediate HER2 expression status.”

About NeuVax™ (nelipepimut-S)

NeuVax™ (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to HLA-A2/A3 molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease-free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. The PRESENT trial is ongoing and additional information on the study can be found at www.neuvax.com. A randomized, multicenter investigator sponsored, 300 patient Phase 2b clinical trial is also enrolling patients to study NeuVax in combination with Herceptin® (trastuzumab; Genentech/Roche).

According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually. Of these women, only about 25% are HER2 positive (IHC 3+). NeuVax targets the approximately 50%-60% of these women who are HER2 low to intermediate (IHC 1+/2+ or FISH < 2.0) and achieve remission with current standard of care, but have no available HER2-targeted adjuvant treatment options to maintain their disease-free status.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product candidates, including patient enrollment in our clinical trials, as well as statements about our expectations, plans and prospects. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

CONTACT: Remy Bernarda
         Senior Director, Communications
         (503) 405-8258
         rbernarda@galenabiopharma.com

(JASO) to Host Q2 Results Conference Call on August 29

SHANGHAI, China, Aug. 20, 2013  — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that it will hold a conference call on Thursday, August 29, 2013, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong Time), to discuss the Company’s second quarter 2013 results.

The company will release its second quarter 2013 results before the market opens that same day.

Dial-in details for the live conference call are as follows:

A live webcast of the conference call will be available on the Company’s website at http://www.jasolar.com.

A replay of the call will be available beginning two hours after the live call.

The dial-in details for the replay are as follows:

About JA Solar Holdings Co., Ltd.

JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation. The Company is one of the world’s largest producers of solar power products. Its standard and high-efficiency product offerings are among the most powerful and cost-effective in the industry. The Company distributes products under its own brand and also produces on behalf of its clients. The Company shipped 1.7 GW of solar power products in 2012. JA Solar is headquartered in Shanghai, China, and maintains production facilities in Shanghai, as well as Hebei, Jiangsu and Anhui provinces.

For more information, please visit www.jasolar.com.

CONTACT: In China

         Nick Beswick
         Brunswick Group
         Tel: +86-10-5960-8600
         E-mail: jasolar@brunswickgroup.com

         In the U.S.

         Cindy Zheng
         Brunswick Group
         Tel: +1-212-333-3810
         E-mail: jasolar@brunswickgroup.com

(ANV) Announces Positive Preliminary Oxidation Test Results

Allied Nevada Gold Corp.
Randy Buffington
President & CEO
(775) 358-4455

Allied Nevada Gold Corp.
Tracey Thom
Vice President, Investor Relations
(775) 789-0119
www.alliednevada.com

(COVR) Selected By Tier 1 Insurance Carrier Division

Cover-All (NYSE MKT:COVR), a leading provider of innovative and modern P/C insurance technology solutions announced today that a division of a nationally well-known Tier 1 insurance company has selected Cover-All’s Business Intelligence Suite (BI) software to execute its information strategy. Cover-All will also provide services to implement Cover-All BI products and work directly with the customer during the implementation.

The newest Cover-All BI customer is a rapidly growing division of a Tier 1 carrier with a significant volume of data from various data sources. To meet today’s needs and prepare for future growth with significant competitive advantages; the customer has selected Cover-All BI and related services to execute their information strategy.

Amongst the key considerations for selecting Cover-All BI were its P/C insurance focus, complete end-to-end BI solution, flexibility to extend the product with customer specific unique needs, significant pre-built and proven functionality and speed of implementation.

The customer is expected to receive the following business benefits after a rapid implementation of Cover-All BI solution:

• Single information platform and distribution of up-to-date information with appropriate details to support information-driven decisions.
• Improved agency engagement through sharing and collaboration of information including performance and trends.
• Improved product selections for the customers for generating cross sales.
• Reduced operating expenses by eliminating significant manual work for information gathering and reconciliation.
• Identification of insurance capacity gaps to invest in profitable programs.

“We are pleased to welcome our new customer to a growing list of Cover-All customers,” said Manish Shah, president and CEO of Cover-All. “Our self-serve, industry focused and scalable BI solution will allow our customer to realize their business benefits quickly. We are looking forward to working with our new customer in executing their information strategy.”

The Cover-All BI solution revealsbusiness insights through significant pre-built and extendable functionality focused on P/C insurance. Cover-All BI is a complete business intelligence and analytics solution with responsive visualization, self-serve tools targeted for business users and many other features. Cover-All provides a robust state-of-the-art, browser-based family of Policy, Business Intelligence, Claims and Studio solutions designed for P/C Insurance to deliver products to market faster, enhance quality, ensure compliance, and reduce costs through operational efficiencies.

About Cover-All Technologies

Cover-All provides P&C insurance professionals a robust state-of-the-art, browser-based family of Policy, Business Intelligence, and Claims solutions designed to deliver products to market faster, enhance quality, ensure compliance, and reduce costs. With offices in Morristown, NJ, Manhattan and Honolulu, Cover-All continues its tradition of developing technology solutions designed to revolutionize the way P&C insurance business is conducted.

Additional information is available online at www.cover-all.com.

(XOMA) Announces Pricing of $27.5 Million Offering of Common Stock

BERKELEY, Calif., Aug. 20, 2013 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), announced today the pricing of 7,596,685 shares of its common stock at a price to the public of $3.62 per share. In addition, XOMA has granted the underwriters a 30-day option to purchase up to an additional 1,139,502 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3. XOMA anticipates its aggregate net proceeds from the offering will be approximately $25.5 million after deducting the underwriting discount and estimated offering expenses payable by XOMA. The offering is expected to close on or about August 23, 2013, subject to customary closing conditions.

Cowen and Company, LLC, is acting as sole book-running manager. Canaccord Genuity Inc. is acting as lead manager, and Roth Capital Partners, LLC, is acting as co-manager.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140. XOMA intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC’s website at www.sec.gov.

About XOMA

XOMA discovers and develops innovative antibody therapeutics.

Forward-Looking Statements

The statements contained herein concerning XOMA’s expectations regarding the completion, size and terms of the proposed offering and the anticipated net proceeds from the offering are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks, including the proposed offering is subject to the satisfaction of customary closing conditions. There can be no assurance that XOMA will be able to complete the offering on the anticipated terms, or at all. Risks and uncertainties relating to XOMA and its business can be found in the “Risk Factors” section of XOMA’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

CONTACT: XOMA Corporation

         Company and Investor Contact:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com

         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com

         Media Contact:
         Canale Communications
         Carolyn Hawley
         619-849-5375
         carolyn@canalecomm.com

(NFEC) Signs Energy Service Contract in Dongguan, China

SHENYANG, China, Aug. 20, 2013  — NF Energy Saving Corporation. (NASDAQ: NFEC) (“NF Energy” or the “Company”), a leading energy saving services and solutions provider for China’s power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries.

On August 13, 2013, the Guangdong division of the Company’s wholly owned subsidiary Liaoning NF Energy signed an energy efficiency service contract with Dongguan Xianjia Plastic Products Company, a Xianhao International Group company, to retrofit 58 units of the client’s injection molding machines (IMM). The project is expected to save energy by up to 40%. In addition, more than 60 units of IMM equipment are lined up for energy service at Xinhao Mold Plastic (Shenzhen) Co., Ltd. For the contracted project, NF Energy will apply its own technologies and many years of experience in motor-drive energy efficiency improvements. A test was conducted by both parties prior to the signing of the contract and the Company’s solution was found to be very effective. With the kickoff of this energy saving project, the Company expects energy service projects like this one in the plastic industry to become a new source of revenue.

Founded in 1989 in Hong Kong, Xianhao International Group (XIG) (http://www.lintall.com.hk) specializes in mould manufacturing, plastic injection molding and secondary processing. In order to meet the increasing market demand, XIG has established production bases in three mainland cities, including Shenzhen in 1992, Dongguan and Ningbo in 2003. XIG plans to improve the energy efficiency in all its facilities.

About NF Energy Saving Corporation

NF Energy Saving Corporation (NASDAQ: NFEC) is a China-based integrated energy conservation solutions provider. The Company’s customers are mainly in the electric power generation (large-scale thermal power generation, hydroelectric power, and nuclear power), water supply, and heat supply industries. The company’s major revenue is from energy efficient flow control solutions including equipment and energy efficiency project services. For more information, visit http://www.nfenergy.com.

Contact Person: Andy Gao
Phone Number: 0086-24-25609775
Email: info@nfenergy.com

(DCIN) The United States of Football – Opens August 23

Film heralded by players and fans – breaks a sports documentary release record A father with insider access asks, “Should I let my kid play?”

WESTFIELD, N.J., Aug. 20, 2013  — DigiNext, the In-Venue Film Festival, a joint venture between Digiplex Destinations (NASDAQ CM: DCIN) and Nehst Media Enterprises, announces the theatrical release of The United States of Football opening in select theaters across the country on August 23. The nationwide release will expand to a wider platform of more than 120 theaters that are members of Screenvision’s 14,000+ theater footprint on August 30 and September 6. The United States of Football is the first title of the new DigiNext 2013-2014 season which includes 12 compelling features.

The movie follows Sean Pamphilon – a father, football fan and filmmaker – as he struggles with the question, “Should I let my kid play?” Sean has an edge in his search for an answer; he’s an Emmy and Peabody Award-winning sports journalist who brought the infamous Bountygate tapes to the public eye.

With insider access to coaches, players and healthcare professionals, Pamphilon’s film documents a dark side of the game – increasing incidence of brain damage, dementia and slow death resulting from repetitive head trauma among professional athletes. The United States of Football takes an intimate first-hand look into the lives of players – once vigorous men with everything to live for, as they lose their minds, their functions and their lives. MRI’s, autopsies and medical research leave little doubt that Chronic Traumatic Encephalopathy (CTE) is a risk for many athletes.

The United States of Football ends in pain and hope – some football legends wither away leaving angry and grieving families; others bravely continue fighting to reform football. Since it all started with kids, The United States of Football examines football coaching and training from Pee Wees to the pros and looks at the steps that can be taken to protect players and ensure both the excitement and integrity of football.

“This feature, which is ultimately all about a topic every parent and thoughtful football fan needs to reflect on, is a milestone for DigiNext and Digiplex,” said Digiplex CEO and Chairman, Bud Mayo. “It is our first truly national release thanks to our recently announced partnership with Screenvision and our many friends in the exhibition industry. With growing media attention on the subject, we hope the conversation continues to widen. If those entrusted with the kids who play can demonstrate to parents they can protect those players, we can save the sport so many of us love.”

“As a father, former college player and coach, it’s a pleasure to bring out this important film and to bring attention to the issue of who is coaching our kids at the youth sports level,” said Nehst Chairman and Founder, Larry Meistrich. “The film also puts a human face on our NFL heroes by calling attention to their lives after the game.”

In conjunction with the movie, audiences can expect in-theater appearances from legendary football stars as well as a live Question and Answer Session with the filmmaker and featured former players opening night. A portion of box office proceeds will go to the Kevin Turner Foundation and the Gridiron Greats Assistance Fund.

Credits: Written and Directed by Sean Pamphilon; Executive Producer, Tenny Priebe; Produced by SP Philms, Documentary – NR (not rated); Running time: 1:41:18

Featuring: Bob Costas, Mike Ditka, Kyle Turley, Jim Brown, John Mackey, Chris Henry, Kurt Warner, Ralph Wenzel, Frank Deford, Justin Strzelczyk, Malcolm Gladwell and James Harrison.

Locations opening The United States of Football on August 23:

AZ – Surprise IMAX

CA – Apple Valley, Bonsall, Oceanside, Poway, San Diego, Temecula, Muvico Thousand Oaks, The Landmark (Los Angeles)

CT – Bloomfield, Lisbon

FL – Pompano 18, Baywalk 20 (St. Petersburg), Centro Ybor (Tampa), Starlight 20 (Tampa), Parisian 20 (W. Palm Beach)

NJ – Westfield

NY –  Quad Cinema (Manhattan)

PA – Bloomsburg, Camp Hill, Reading, Selinsgrove, Williamsport

OH – Solon, Muvico Rosemont Cinema (Chicago)

Visit www.diginextfilms.com for series information. Visit www.theusof.com for up-to-date information on theater screening schedules, locations and advance ticket sales for The United States of Football.

About Nehst

Nehst Media Enterprises is a content financing, development, production and distribution company innovating in many facets of the entertainment world. Nehst is founded on the premise that today’s media landscape requires content development and distribution focused on niche marketing, community and branding. Nehst applies unique strategies to information technology to discover, produce and distribute content people care about. More information about Nehst is available at www.nehst.com. You can also connect with Nehst via Facebook, Twitter and YouTube.

About Digital Cinema Destinations Corp. (www.digiplexdest.com)

Digital Cinema Destinations Corp. (NasdaqCM: DCIN) is Digiplex Destinations, dedicated to transforming its movie theaters into interactive entertainment centers. The Company provides consumers with uniquely satisfying experiences, combining state-of-the-art digital technology with engaging, dynamic content that far transcends traditional cinematic fare. The Company’s customers enjoy live opera, ballet, Broadway shows, sports events, concerts and, on an ongoing basis, the very best major motion pictures. Digiplex operates 19 cinemas and 184 screens in AZ, CA, CT, OH, PA, and NJ. You can connect with Digiplex via Facebook, Twitter, YouTube and Blogger.

(SUPN) Final FDA Approval and Upcoming Launch of Trokendi XR(TM)

ROCKVILLE, Md., Aug. 19, 2013 — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received final approval from the Food & Drug Administration (the “FDA”) for Trokendi XR, a novel once-daily extended release formulation of topiramate for the treatment of epilepsy. The company expects to launch the product and for it to be available in pharmacies over the next few weeks.

The approval letter states that the FDA has completed its review of the application and that Trokendi XR is approved effective August 16, 2013 for use as recommended in the agreed-upon labeling. The FDA granted a waiver for certain pediatric study requirements and a deferral for submission of post-marketing pediatric pharmacokinetic assessments that are due in 2019 followed by clinical assessments in 2025.

“We are very excited about the approval of Trokendi XR and its upcoming launch. This is excellent news for Supernus, its shareholders, and patients with epilepsy. We remain committed to the epilepsy community and very much look forward to now having two products, Trokendi XR and Oxtellar XR, available to patients,” said Jack Khattar, Chief Executive Officer, President and Director of Supernus.

About Trokendi XR™

Trokendi XR is a novel once- daily extended release formulation of topiramate. Trokendi XR is an antiepileptic drug (AED) indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures, and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product will be available in 25mg, 50mg, 100mg and 200mg extended-release capsules.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward Looking Statements

This press release contains forward-looking statements regarding the potential for Trokendi XR to treat epilepsy, and the timing of the product’s availability to physicians. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company’s ability to commercialize the product successfully, whether physicians will prescribe and patients will use the product, once available, and competition in the market. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s Annual Report Form 10-K that was filed with the United States Securities and Exchange Commission on March 15, 2013 and under the caption “Risk Factors” and the updates to these risk factors in the Company’s quarterly report form 10-Q that was filed with the Commission on August 15, 2013. Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update or revise these statements, except as may be required by law.

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591

(EDS) Announces Receipt of Non-binding Going Private Proposal

FUJIAN, China, Aug. 19, 2013 /PRNewswire-FirstCall/ — Exceed Company Ltd. (NASDAQ: EDS) (“Exceed” or “the Company”), one of the leading domestic sportswear brands in China, today reported that its board of directors (the “Board of Directors”) has received a preliminary, non-binding proposal from its chairman and chief executive officer, Mr. Shuipan Lin (“Mr. Lin”) and his affiliates (including Tiancheng Int’l Investment Group Limited), HK Haima Group Limited, Wisetech Holdings Limited, Windtech Holdings Limited and RichWise International Investment Group Limited (collectively, the “Consortium Members”). The Consortium Members propose to acquire all of the outstanding ordinary shares of the Company not currently owned by them at a proposed price of $1.72 per ordinary share in cash as part of a going private transaction, subject to certain conditions. The proposal represents a premium of 15% to the closing price of the ordinary shares of the Company on August 16, 2013, a premium of 38% to the average closing price of the ordinary shares of the Company during the last 30 trading days, and a premium of 42% to the average closing price of the ordinary shares of the Company during the last 60 trading days. As of August 17, 2013, the Consortium Members in the aggregate owned approximately 66.5% of the total outstanding ordinary shares of the Company. A copy of the text of the proposal letter to the Board of Directors is attached as Exhibit A.

In response, the Board of Directors has formed a special committee (the “Special Committee”) consisting of Messrs. Jin Jichun, Chen Yea-Mow and Pang Xiaozhong, each an independent non-executive director, to consider this proposal. Mr. Jin will be the Chairman of the Special Committee. The Special Committee will retain a financial advisor and legal counsel to assist it in its work.

The Board of Directors cautions the Company’s shareholders and others considering trading in its securities that the Board of Directors has just received the non-binding proposal from the Consortium Members and that no decisions have been made by the Special Committee with respect to the Company’s response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

About Exceed Company Ltd.

Exceed Company Ltd. designs, develops and engages in wholesale of footwear, apparel and accessories under its own brand, XIDELONG, in China. Since it began operations in 2002, Exceed has targeted its growth on the consumer markets in second and third-tier cities in China. Exceed has three principal categories of products: (i) footwear, which comprises running, leisure, basketball, skateboarding and canvas footwear, (ii) apparel, which mainly comprises sports tops, pants, jackets, track suits and coats, and (iii) accessories, which mainly comprise bags, socks, hats and caps. Exceed Company Ltd. currently trades on Nasdaq under the symbol “EDS”.

Forward-Looking Statements:

This announcement contains forward-looking statements that are based on our current expectations, assumptions, estimates and projections about us and our industry. All statements other than statements of historical fact in this form are forward-looking statements. These forward-looking statements can be identified by words or phrases such as “may”, “will”, “expect”, “anticipate”, “estimate”, “plan”, “believe”, “is/are likely to” or other similar expressions.

These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, we cannot assure you that our expectations will turn out to be correct. Our actual results could be materially different from and worse than our expectations. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to changes in our goals and strategies, our ability to control costs and expenses, success of our products, competition in the sportswear industry in China, and changes in PRC government preferential tax treatment and financial incentives. The forward-looking statements made in this announcement relate only to events or information as of the date on which this announcement is published. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date this announcement is published or to reflect the occurrence of unanticipated events.

For further information, please contact:

Investor Relations
Exceed Company Ltd.
Vivien Tai
+852 2153-2771
ir@xdlong.cn
Exhibit A

August 17, 2013

The Board of Directors
Exceed Company Ltd.
Unit F, 24/F, China Overseas Building
139 Hennessy Road, Wanchai
Hong Kong

Dear Members of the Board of Directors,

We, Shuipan Lin and his affiliates (including Tiancheng Int’l Investment Group Limited), HK Haima Group Limited, Wisetech Holdings Limited, Windtech Holdings Limited and RichWise International Investment Group Limited (collectively, the “Consortium Members“), are pleased to submit this preliminary non-binding proposal (the “Proposal“) to acquire all of the outstanding ordinary shares of Exceed Company Ltd. (the “Company“) that are not already owned by us in a “going private” transaction on the principal terms and conditions described in this letter (the “Transaction“).

We believe that our Proposal of US$1.72 per ordinary share of the Company in cash provides a very attractive opportunity to the Company’s shareholders. Our Proposal represents a premium of 15% to the closing price of the ordinary shares of the Company on August 16, 2013, a premium of 38% to the average closing price of the ordinary shares of the Company during the last 30 trading days and a premium of 42% to the average closing price of the ordinary shares of the Company during the last 60 trading days. As of the date hereof, the Consortium Members in the aggregate own approximately 66.5% of the total outstanding ordinary shares of the Company.

Set forth below are the key terms of our Proposal.

I. Transaction and Purchase Price

We propose to acquire all of the outstanding ordinary shares of the Company not already owned by us at a purchase price equal to US$1.72 per ordinary share in cash through a one-step merger of an acquisition vehicle newly formed by the Consortium Members with and into the Company. Please note that the Consortium Members are currently interested only in pursuing the Transaction and are not interested in selling their shares in any other transaction involving the Company.

II. Sources of Financing

We intend to finance the Transaction with a combination of equity and debt capital funded by Mr. Shuipan Lin.

III. Definitive Documentation

Consummation of the Transaction would require negotiation and execution of a definitive merger agreement, as well as other customary agreements for a transaction of this nature, each containing terms and conditions appropriate for transactions of this type. We have retained Skadden, Arps, Slate, Meagher & Flom LLP as our international legal counsel and are prepared to provide draft agreements promptly.

IV. Confidentiality

We intend to promptly file a joint Schedule 13D to disclose this Proposal and our intention as set out in this Proposal. However, we are sure you will agree that it is in all of our interests to ensure that we proceed in a confidential manner, unless otherwise required by law, until we have executed the definitive agreements or terminated our discussions.

V. Process

We believe that the Transaction will provide superior value to the Company’s public shareholders. We recognize that the board of directors will evaluate the Proposal independently before it can make a decision to endorse it. Given our involvement in the Transaction, we would expect that the independent members of the board of directors will proceed to consider our Proposal and the Transaction.

VI. No Binding Commitment

This Proposal is not a binding offer, agreement or agreement to make a binding offer or agreement at any point in the future. This letter is a preliminary indication of interest by the Consortium Members and does not contain all matters upon which agreement must be reached in order to consummate the proposed Transaction, nor does it create any binding rights or obligations in favor of any person. The parties will be bound only upon the execution of mutually agreeable definitive documentation.

In closing, we would like to express our commitment to working together with the board of directors of the Company to bring this Transaction to a successful and timely conclusion. Should you have any questions regarding this Proposal, please do not hesitate to contact us. We look forward to hearing from you.

Sincerely,

SHUIPAN LIN

By: /s/ Shuipan Lin

TIANCHENG INT’L INVESTMENT GROUP LIMITED

By: /s/ Shuli Chen
Name:   Shuli Chen
Title:     Director

HK HAIMA GROUP LIMITED

By: /s/ Huixin Zhuang
Name:   Huixin Zhuang
Title:     Director

WISETECH HOLDINGS LIMITED

By: /s/ Wong Kok Wai
Name:   Wong Kok Wai
Title:     Director

WINDTECH HOLDINGS LIMITED

By: /s/ Wong Kok Wai
Name:   Wong Kok Wai
Title:     Director

RICHWISE INTERNATIONAL INVESTMENT GROUP LIMITED

By: /s/ Jinlei Shi
Name:   Jinlei Shi
Title:     Director

(BLRX) Appoints B. J. Bormann to Board of Directors

JERUSALEM, Aug. 19, 2013 — BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today the appointment of B. J. Bormann, Ph.D., to its Board of Directors.

Dr. Bormann has had a distinguished and extensive career in the pharmaceutical industry. Most recently, she served as Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer Ingelheim Pharmaceuticals Inc. Prior to that, she held the position of Vice President, Strategic Alliances, at Pfizer Inc.

Commenting on the new appointment, Aharon Schwartz, Ph.D., Chairman of the Board of BioLineRx, said, “With a career spanning more than two decades at senior executive positions in leading pharmaceutical companies, B.J. brings a wealth of industry-tested knowledge, experience, and leadership, making her a valuable addition to our Board. She offers BioLineRx tremendously deep insight and an impressive track record in precipitating partnerships and alliances, as we continue to grow our Company and advance our therapeutic pipeline toward commercialization. On behalf of the entire team at BioLineRx, I am very pleased to welcome B.J. to our Board.”

“I am delighted to join BioLineRx’s Board of Directors,” said Dr. Bormann. “I believe the Company has a very bright future, given its promising therapeutic product pipeline and drug development expertise. I am looking forward to working alongside BioLineRx’s experienced management team as they continue to advance the Company’s pipeline and forge new strategic collaborations within the industry.”

Dr. Bormann recently retired from Boehringer Ingelheim Pharmaceuticals Inc., where she served as Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships and, before that, as Senior Vice President, Business Development and Licensing. At Boehringer Ingelheim, Dr. Bormann was responsible for global scouting and evaluation of new partnership opportunities, as well as various business structures, including acquisitions, alliances, joint ventures and equity stakes. She was also a member of the Corporate Management Committee for the United States. Before joining Boehringer, Dr. Bormann held a number of senior positions at Pfizer, including Vice President, Strategic Alliances. Dr. Bormann has served, and continues to serve, on several boards, including the Executive Board of the Connecticut Business and Industry Association, Rincon Pharmaceuticals, Supportive Therapeutics, Institute for Pediatric Innovation and the Biotechnology Industrial Organization (BIO). In addition, she has served as a strategic consultant to Paperboy Ventures, ACG & Associates, and Atlas Venture.

She is currently the CEO of Harbour Antibodies and also Chief Business Officer of NanoMedical Systems, Inc.

Dr. Bormann earned a B.S. in Biology and Chemistry from Fairfield University and received her Ph.D. in Biomedical Science from the University of Connecticut Health Center in the Department of Pathology. Upon receiving her Ph.D., Dr. Bormann worked as a research affiliate in the Department of Pathology at the Yale University School of Medicine.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase 1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has commenced a Phase 2 study; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for schizophrenia. In addition, BioLineRx has four products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government’s Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com, the content of which does not form a part of this press release.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:
KCSA Strategic Communications
Garth Russell / Todd Fromer
+1 212-896-1250 / +1 212-896-1250
grussell@kcsa.com / tfromer@kcsa.com

or

Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il

(CRNT) Deploys FirstNet-Ready Public Safety Network throughout Nebraska

Deployment includes over 200 links throughout the state, providing vital connectivity in rural areas

ANAHEIM, Calif., Aug. 19, 2013 — APCO 2013 — Ceragon Networks Ltd. (NASDAQ: CRNT), the #1 wireless backhaul specialist, today announced that it has received orders for the new Nebraska Regional Interoperability Network (NRIN).  The network, which is managed by Communication Services Inc. (CSI), includes approximately 200 links of Ceragon’s FirstNet-ready FibeAir solutions providing critically-needed connectivity and improved capacity for First Responders, particularly in the vast rural areas of Nebraska, the 9th least-densely populated state of the United States.

The NRIN will be using new and existing resources to create a statewide wireless communication system for a variety of state public safety agencies. The system will connect the public safety answering points (PSAPs) and 911 centers, enabling the smooth and efficient interoperability of the separate first responder networks.  The network will also be used by the Public Power Districts.  In the future, local public safety agencies may be able to subscribe to the system.

“We have been deploying Ceragon solutions in our new public safety network since 2011 and their reliability and resilience has been proven repeatedly,” said Tim Hofbauer, Director of Columbus and Platte County Emergency Management, Nebraska. “Ceragon’s FirstNet-ready solutions have ensured that our first responders have the network capacity, connectivity and agency-interoperability they need in order to do their jobs and save lives.”

“We are committed to the North American market and are proud to play an integral part in the NRIN’s public safety network,” said Ira Palti, President and CEO of Ceragon Networks.  “Our recently launched platforms for the North American market are designed specifically to meet the demanding requirements of the network operators in this important region.”

“The public safety community is moving more and more towards LTE-based networks, and as a result, organizations are insisting upon high-capacity, high-power and high-resilience solutions,” said Chuck Meyo, President of Ceragon North America. “The need to ensure disaster recovery-standard operational capabilities is an absolute priority and Ceragon solutions are ideally suited for this.”

About Ceragon Networks Ltd.

Ceragon Networks Ltd. (NASDAQ: CRNT) is the #1 wireless backhaul specialist.  We provide innovative, flexible and cost-effective wireless backhaul and fronthaul solutions that enable mobile operators and other wired/wireless service providers to deliver 2G/3G, 4G/LTE and other broadband services to their subscribers.  Ceragon’s high-capacity, solutions use microwave technology to transfer voice and data traffic while maximizing bandwidth efficiency, to deliver more capacity over longer distances under any deployment scenario. Based on our extensive global experience, Ceragon delivers turnkey solutions that support service provider profitability at every stage of the network lifecycle enabling faster time to revenue, cost-effective operation and simple migration to all-IP networks.  As the demand for data pushes the need for ever-increasing capacity, Ceragon is committed to serve the market with unmatched technology and innovation, ensuring effective solutions for the evolving needs of the marketplace. Our solutions are deployed by more than 430 service providers in over 130 countries

Join the discussion:

LinkedIn: http://www.linkedin.com/company/14470
Facebook: https://www.facebook.com/ceragonnetworks
Twitter: https://twitter.com/Ceragon
Youtube: http://www.youtube.com/user/CeragonNetworks?featur
Backhaul Forum: http://www.backhaulforum.com/

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON ® is a trademark of Ceragon Networks Ltd., registered in various countries.  Other names mentioned are owned by their respective holders.

This press release may contain statements concerning Ceragon’s future prospects that are “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and projections that involve a number of risks and uncertainties. There can be no assurance that future results will be achieved, and actual results could differ materially from forecasts and estimates. These are important factors that could cause actual results to differ materially from forecasts and estimates. Some of the factors that could significantly impact the forward-looking statements in this press release include the risk of significant expenses in connection with potential contingent tax liability associated with Nera’s prior operations or facilities, risks associated with unexpected changes in customer demand, risks associated with increased working capital needs, and other risks and uncertainties, which are discussed in greater detail in Ceragon’s Annual Report on Form 20-F and Ceragon’s other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and Ceragon undertakes no commitment to revise or update any forward-looking statement in order to reflect events or circumstances after the date any such statement is made. Ceragon’s public filings are available from the Securities and Exchange Commission’s website at www.sec.gov or may be obtained on Ceragon’s website at www.ceragon.com

(EVAC) to Be Acquired by Atlas Copco Group

Edwards’ Shareholders to Receive Consideration of Up to $10.50 Per Share in Cash

Transaction Valued at Up to Approximately $1.6 Billion Including Debt

CRAWLEY, West Sussex, United Kingdom, Aug. 19, 2013 — Edwards Group Limited (Nasdaq:EVAC) (“Edwards”) a leading developer and manufacturer of sophisticated vacuum products, abatement systems and related value-added services, and Atlas Copco Group (NASDAQ OMX Stockholm: ATCO A, ATCO B) (“Atlas Copco”), the Sweden-based provider of industrial productivity solutions, today announced that the companies have entered into a definitive merger agreement in a transaction valued at up to approximately $1.6 billion, including the assumption of debt.

Under the terms of the merger agreement, a subsidiary of Atlas Copco will acquire Edwards for a per-share consideration of up to $10.50, which includes a fixed cash payment of $9.25 at closing and an additional payment of up to $1.25 per share post-closing, depending on Edwards’ achievement of 2013 revenue within the range of £587.5 million to £650 million and achievement of a related Adjusted EBITDA¹ target within the range of £113.9 million to £145 million. The transaction is expected to close in the first quarter of 2014.

Depending on the amount of any additional payment, the merger consideration represents a premium of approximately 11% to 26% to Edwards’ 30 day average closing share price of $8.33 up to August 16, 2013, the last trading day prior to this announcement. Edwards priced its initial public offering on The NASDAQ Global Select Market on May 10^th 2012 at $8.00 per share.

Edwards’ shareholders representing approximately 84% of the current shares outstanding have entered into voting agreements with Atlas Copco to vote in favor of the merger, subject to the conditions set out in the voting agreements. Further, the Board of Directors of Edwards unanimously recommends the offer to all Edwards shareholders.

Edwards and Atlas Copco have a complementary businesses fit. Both companies share a similar strategic direction, with growth focused on technology leadership and customer service. The benefits of greater scale will help accelerate Edwards’ growth strategy and provide more opportunities for Edwards’ employees. Upon completion of the transaction, a new Vacuum Solutions Division will be formed within the Atlas Copco Compressor Technique business area, with headquarters in Crawley, UK.

Jim Gentilcore, Chief Executive Officer of Edwards, said, “This strategically and financially compelling transaction provides the opportunity for our stockholders to receive an attractive premium for their shares. On top of the cash payment at closing, analyst consensus for the full year and our strong start to the third quarter leads us to believe it is realistic for us to achieve the results that would deliver an additional cash payment towards the upper end of the range to our shareholders.”

Gentilcore continued, “This transaction also delivers many benefits for Edwards’ customers and employees. The two companies share very similar strategic goals, strong brands and leading market positions. The Edwards brand and reputation will benefit from the support, expertise and financial strength that Atlas Copco will bring.”

Ronnie Leten, President and CEO of Atlas Copco, said, “We recognize the strength of Edwards’ people and products as well as their excellence in technology and innovation. We are excited that this professional company will join our Group.”

The merger, which has been unanimously approved by the Boards of Directors of both companies, is subject to shareholder approval, antitrust clearance, and customary closing conditions.

Barclays and Lazard acted as financial advisors to Edwards on the transaction. Legal advisors to Edwards are Davis Polk & Wardwell London LLP, Weil Gotshal & Manges LLP and Maples & Calder.

Analyst Conference Call

The Company will conduct a conference call today at 8:00 AM Eastern Time to discuss the transaction details. The U.S. dial in number for the call is 877-246-9875 and the non-U.S. dial in number is 707-287-9353. The passcode is 34161991. A live webcast of the conference call will also be available on the investor relations page of the Company’s website at www.edwardsvacuum.com.

For those unable to participate in the conference call, a replay will be available for one week following the call. To access the replay, the U.S. dial in number is 855-859-2056 and the non-U.S. dial in number is 404-537-3406. The replay passcode is 34161991. A replay of the call will be available by webcast for an extended period of time at the Company’s website, at www.edwardsvacuum.com.

About Edwards

Edwards is a leading developer and manufacturer of sophisticated vacuum products, abatement systems and related value-added services. These are integral to manufacturing processes for semiconductors, flat panel displays, LEDs and solar cells; are used within an increasingly diverse range of industrial processes including power, glass and other coating applications, steel and other metallurgy, pharmaceutical and chemical; and for both scientific instruments and a wide range of R&D applications.

Edwards has over 3,200 full-time employees and 500 temporary workers operating in approximately 30 countries worldwide engaged in the design, manufacture and support of high technology vacuum and exhaust management equipment.

Edwards’ American Depositary Shares trade on The NASDAQ Global Select Market under the symbol EVAC. Further information about Edwards can be found at www.edwardsvacuum.com.

About Atlas Copco

Atlas Copco is an industrial group with world-leading positions in compressors, expanders and air treatment systems, construction and mining equipment, power tools and assembly systems. The company was founded in 1873, is based in Stockholm, Sweden, and has a global reach spanning more than 170 countries.

¹For the reconciliation of Adjusted EBITDA to EBITDA, please see Edwards’ quarterly SEC filings or quarterly earnings presentation which can be found in the investor relations tab on its website, www.edwardsvacuum.com.

Cautionary Statement Concerning Forward-Looking Statements

This release includes forward-looking statements, beliefs or opinions, including statements with respect to the Company’s business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Company’s control and all of which are based on management’s current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as “believe,” “expects,” “may,” “will,” “could,” “should,” “shall,” “risk,” “intends,” “estimates,” “aims,” “plans,” “predicts,” “continues,” “assumes,” “positioned” or “anticipates” or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements are based on management’s current expectations, but are subject to a number of important factors, risks, uncertainties and assumptions that may cause the actual results to be materially different from those expectations reflected in such forward-looking statements, including but not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the risk that a closing condition to the proposed merger may not be satisfied; the failure to receive, on a timely basis or otherwise, the required approvals by the Company’s shareholders and government or regulatory agencies; the ability of the Company to retain and hire key personnel and maintain relationship with customers, suppliers and other business partners pending the consummation of the proposed merger, factors affecting the amount of the additional payment component of the merger consideration; and other factors described in “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2012. The forward-looking statements are based on management’s current views and assumptions regarding future events and speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the securities laws.

Additional Information

In connection with the proposed transaction, the Company will furnish to the SEC a proxy statement and relevant documents concerning the proposed transaction relating to the solicitation of proxies to vote at a special meeting of shareholders to be called to approve the proposed transaction, which will include a detailed description of the merger arrangements and a copy of the merger agreement. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT BECOMES AVAILABLE BECAUSE THE PROXY STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. You may obtain copies of all documents furnished to the SEC regarding this transaction, free of charge, at the SEC’s website (sec.gov). You will also be able to obtain these documents, free of charge (when available) from the Company’s website, www.edwardsvacuum.com.

EVAC-F

CONTACT: Investor Relations:

         Ross Hawley
         Head of Investor Relations
         Edwards
         +44 (0)1293 528844
         investors@edwardsvacuum.com

         Monica Gould
         The Blueshirt Group
         +1 212 871-3927
         monica@blueshirtgroup.com

(EFUT) Engage Rainbow Department Store on myStore Platform

BEIJING, Aug. 19, 2013 — eFuture Information Technology Inc. (Nasdaq:EFUT) (the “Company” or “eFuture”), a leading provider of software and services in China’s rapidly growing retail and consumer goods industries, today announced that it has signed an agreement with Rainbow Department Store Company Limited (002419, “Rainbow Department Store”) to launch myStore, a one-on-one engagement platform designed to facilitate easy access between sales clerks and their customers. The platform also provides a social shopping network for consumers and their friends to connect to the consumer society at large.

Established in 1984 and listed on the Shenzhen Stock Exchange in 2010, Rainbow Department Store, with its two brands “Rainbow” and “Dreams-on”, has been recognized as one of the Top 100 Chain Retailers of China for 12 consecutive years. By April 2013, Rainbow owns 55 stores in major provinces across China and manages two franchised department stores. Dreams-on owns two regular stores.

With the contract signed in July, eFuture pledged to provide three stores owned by Rainbow Department Store with integrated services such as mobile marketing, mobile shopping, and membership management to monitor and gather information on consumer behavior, such as purchasing patterns and reaction to marketing campaigns, through eFuture’s renowned data analytics capabilities.

ABOUT EFUTURE INFORMATION TECHNOLOGY INC.

eFuture Information Technology Inc. (Nasdaq:EFUT) is a leading provider of software and services in China’s rapidly growing retail and consumer goods industries. eFuture provides integrated software and services to manufacturers, distributors, wholesalers, logistics companies and retailers in China’s front-end supply chain (from factory to consumer) market, especially in the retail and fast moving consumer goods industries. For more information about eFuture, please visit http://www.e-future.com.cn.

SAFE HARBOR

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. eFuture may also make written or oral forward-looking statements in periodic reports to the Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to second parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: eFuture’s anticipated growth strategies; eFuture’s future business development, results of operations and financial condition; expected changes in the Company’s revenue and certain cost or expense items; eFuture’s ability to attract clients and leverage its brand; trends and competition in the software industry; the Company’s ability to control expenses and maintain profit margins; the Company’s ability to hire, train and retain qualified managerial and other employees; the Company’s ability to develop new software and pilot new business models at desirable locations in a timely and cost-effective manner; the performance of third parties under contracts with the Company; the expected growth of the Chinese economy software market in retail and consumer goods industries; and Chinese governmental policies relating to private managers and operators of software and applicable tax rates.

Further information regarding these and other risks will be included in eFuture’s annual report on Form 20-F and other documents filed with the SEC. All information provided in this press release and in the attachments is as of August 13, 2012, and the Company undertakes no duty to update such information or any other forward-looking information, except as required under applicable law.

CONTACT: Investor Contact:
         Troe Wen, Company Secretary
         eFuture Information Technology Inc.
         +86 10 5293 7699

(APEI) to Webcast Third Quarter 2013 Results Conference Call

American Public Education, Inc. (NASDAQ: APEI) – parent company of online learning provider American Public University System, which operates through American Military University and American Public University – plans to release third quarter 2013 results after the close of U.S. financial markets on November 6, 2013.

A live webcast of its third quarter 2013 earnings conference call will be broadcast at 5:00 p.m. Eastern time on Wednesday, November 6, 2013. This call will be open to listeners through the webcast section of the Company’s investor relations website, www.AmericanPublicEducation.com. A replay of the live webcast will also be available starting approximately one hour after the conclusion of the live conference call. The replay will be archived and available to listeners for one year.

Webcast: http://www.americanpubliceducation.com/phoenix.zhtml?c=214618&p=irol-presentations

American Public Education, Inc.

American Public Education, Inc. (NASDAQ: APEI) is an online provider of higher education focused primarily on serving the military and public service communities. American Public University System (APUS), wholly owned by APEI, operates through American Military University (AMU) and American Public University (APU). APUS serves over 100,000 adult learners worldwide and offers more than 90 degree programs in fields ranging from homeland security, military studies, intelligence, and criminal justice to technology, business administration, public health, and liberal arts. Nationally recognized for its best practices in online higher education, APUS provides an affordable education through classes taught by experienced faculty who are leaders in their fields and committed to the academic achievement of their students.

American Public University System is accredited by The Higher Learning Commission and is a member of the North Central Association of Colleges and Schools (www.ncahlc.org). For more information about APUS graduation rates, median debt of students who completed programs, and other important information, visit www.apus.edu/disclosure.

(MBWM) Acquisition of Firstbank Corporation

SAN DIEGO and ALMA, Mich., Aug. 16, 2013  — Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Firstbank Corporation (NASDAQ: FBMI) (“Firstbank”) by Mercantile Bank Corporation (NASDAQ: MBWM) (“Mercantile Bank”).  On August 15, 2013, Firstbank and Mercantile Bank announced the signing of a definitive merger agreement whereby Firstbank shareholders will receive 1.0 shares of Mercantile Bank stock for each share of Firstbank stock, an equivalent of $18.77 per share.  The merger is expected to close by December 31, 2013.

Is the Merger Best for Firstbank and Its Shareholders?

Robbins Arroyo LLP’s investigation focuses on whether the board of directors at Firstbank is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger.  The $18.77 merger consideration represents a premium of only 12.67% based on Firstbank’s closing price on August 14, 2013, the last day prior to the announcement of the merger.  The 12.67% premium is substantially below the average premium of 28.21% for comparable transactions over the past three years.

In addition, on July 22, 2013, the company announced its financial results for the second quarter 2013.  Notably, earnings per share of $.38 were 52% over the $.25 earnings per share of second quarter 2012.  Further, Firstbank exceeded analyst earnings per share, net income, and sales expectations in seven of the last eight quarters.  In response to the positive financial report, Thomas R. Sullivan, President and Chief Executive Officer of Firstbank, stated that: “The second quarter of 2013 saw significant progress for our company,” noting “[w]ith the growth in loans, we saw the first quarterly increase in our yield on earning assets since the third quarter 2007.”

Given these facts, Robbins Arroyo is examining Firstbank’s board of directors’ decision to sell the company to Mercantile Bank now rather than allow shareholders to continue to participate in the company’s continued success and future growth prospects.

Firstbank shareholders have the option to file a class action lawsuit to secure the best possible price for shareholders and the disclosure of material information so shareholders can vote on the transaction in an informed manner.  Firstbank shareholders interested in information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm’s website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/firstbank-corporation

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
ddonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

(UFCS) Declares Common Stock Cash Dividend

CEDAR RAPIDS, Iowa, Aug. 16, 2013 (GLOBE NEWSWIRE) — Today, the Board of Directors of United Fire Group, Inc. (Nasdaq:UFCS) (the “Company”) declared a common stock quarterly cash dividend of $0.18 per share. This dividend will be payable September 16, 2013, for shareholders of record as of September 3, 2013. The Company has consistently paid a quarterly dividend since March 1968.

About United Fire Group, Inc.:

Founded in 1946 as United Fire & Casualty Company, United Fire Group, Inc., through its insurance company subsidiaries, is engaged in the business of writing property and casualty insurance and life insurance as well as selling annuities.

Through our subsidiaries, we are licensed as a property and casualty insurer in 43 states, plus the District of Columbia, and we are represented by approximately 1,200 independent agencies. The United Fire pooled group is rated “A” (Excellent) by A.M. Best Company.

Our subsidiary, United Life Insurance Company, is licensed in 36 states, represented by more than 900 independent life agencies and rated an “A-” (Excellent) by A.M. Best Company.

For more information about United Fire Group, Inc. visit www.unitedfiregroup.com.

CONTACT: Anita Novak, Director of Investor Relations
         319-399-5251 or alnovak@unitedfiregroup.com

(GLOW) Announces Exchange of Series B-1 Preferred Stock

Glowpoint, Inc. (NYSE MKT: GLOW), a leading provider of cloud-based video collaboration, network and support services, announced today that the Company entered into a Series B-1 Preferred Exchange Agreement (the “Agreement”), by and between the Company and GP Investment Holdings, LLC (“GPI”), whereby, the Company agreed to exchange (the “Exchange Transaction”) 95 shares (the “B-1”) of the Company’s Series B-1 Preferred Stock (the “Preferred Stock”) held by GPI for 6,333,333 shares of the Company’s common stock, par value $0.0001 per share (the “Exchange Shares”). The Exchange Transaction closed on August 9, 2013.

The 95 shares of B-1 Preferred Stock held a liquidation preference of $9,736,000 as of August 9, 2013 and were exchanged into shares of common stock at an effective conversion price of $1.54. Following the completion of the exchange transaction, GPI holds 15,276,138 shares of the Company’s common stock. This includes the 6,333,333 Exchange Shares and 8,924,805 common shares that were purchased along with the B-1 Preferred directly from Vicis Capital Master Fund in a private transaction.

“We were very pleased to execute the Exchange Transaction as we believe this benefits the Company and our common stockholders by reshaping and simplifying our capital structure, retiring $9,736,000 of liquidation preference, eliminating the dividends on this preferred stock and adding stable long term investors,” said Peter Holst, President and CEO of Glowpoint. “We are pleased to welcome GPI as an investor. GPI is an investment vehicle affiliated with Main Street Capital, a leading middle market BDC headquartered in Houston, and the Pessin family, who are highly respected value investors based in New York.”

In connection with the Agreement, the Company entered into a Registration Rights Agreement (the “Registration Agreement”), with GPI, whereby, the Company has agreed to use its best efforts to file a registration statement, covering the 6,333,333 Exchange Shares, with the Securities and Exchange Commission no later than ninety (90) days after August 9, 2013. Pursuant to the Registration Agreement, GPI has, subject to customary exceptions, agreed to a one (1) year lock-up of its shares.

Supporting Link:

• Glowpoint Investor Information

About Glowpoint

Glowpoint, Inc. (NYSE MKT: GLOW) provides video collaboration, network, and support services to large enterprises and mid-sized companies to support their unified communications (UC) strategies and business goals. More than 1,000 organizations in 96 countries rely on our unmatched experience, business-class support and cloud-based services to collaborate with colleagues, business partners, and customers more effectively. To learn more please visit www.glowpoint.com.

Forward looking and cautionary statements

The information in this release may contain statements that are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance and availability of new video communications services; the non-exclusive and terminable-at-will nature of sales agreements; rapid technological change affecting demand for our services; competition from other video communication service providers; and the availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission. We make no representation or warranty that the information contained herein is complete and accurate; we have no duty to correct or update any information.